IMCR (Immunocore Holdings) Total Stockholders Equity: $419.8 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

IMCR Immunocore Holdings PLC IMCR
81 GF Score
Price $31.59
GF Value $45.37
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Immunocore Holdings Total Stockholders Equity?

Immunocore Holdings IMCR -0.74% 81 Total Stockholders Equity is $419.8 Mil as of Jun. 2026. GuruFocus rates IMCR with a GF Score™ of 81/100 and a GF Value™ of $45.37 (Possible Value Trap). The stock has 3 warning signs investors should review.

Immunocore Holdings's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $419.8 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Immunocore Holdings's Book Value per Share for the quarter that ended in Jun. 2026 was $8.15. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Immunocore Holdings's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.94.

Immunocore Holdings  (NAS:IMCR) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Immunocore Holdings's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(419.798-0)/51.480159
=8.15

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Immunocore Holdings's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 394.206) / 419.798
=0.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunocore Holdings Total Stockholders Equity Related Terms

Immunocore Holdings Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Immunocore Holdings's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunocore Holdings Total Stockholders Equity Chart

Immunocore Holdings Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Stockholders Equity
Get a 7-Day Free Trial 232.35 335.32 368.84 360.72 381.03

Immunocore Holdings Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 388.48 396.56 381.03 393.67 419.80
IMCR
81GF Score
Immunocore Holdings PLC IMCR
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $419.8 Mil mean?
Immunocore Holdings (IMCR) has a Total Stockholders Equity of $419.8 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Immunocore Holdings and its competitors.
Is Immunocore Holdings' Total Stockholders Equity too high?
Immunocore Holdings' current Total Stockholders Equity is $419.8 Mil. Overall, Immunocore Holdings has a GF Score™ of 81/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Total Stockholders Equity compare to TSHA and KARD?
Immunocore Holdings' Total Stockholders Equity of $419.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Immunocore Holdings and its competitors. Immunocore Holdings's current Total Stockholders Equity is $419.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Possible Value Trap. The stock's GF Value™ is $45.37, compared to a current price of $31.59 — trading 30.4% below its estimated fair value. The current Total Stockholders Equity is $419.8 Mil. Immunocore Holdings' overall GF Score™ is 81/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Total Stockholders Equity is $419.8 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Immunocore Holdings (IMCR) Overvalued in 2026?

Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued. The current stock price of $31.59 is trading 30.4% below its estimated GF Value™ of $45.37. GuruFocus considers Immunocore Holdings to be Possible Value Trap.

Key valuation signals for IMCR:

  • Total Stockholders Equity: $419.8 Mil
  • GF Value™: $45.37 vs. price of $31.59 (30.4% below fair value)
  • GF Score™: 81/100 with 3 warning signs

No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Immunocore Holdings Business Description

Other Exchanges 6YG:Germany
Address 92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
81GF Score

Get the complete analysis for IMCR

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$31.59
Price
$45.37
GF Value